Cost of management of invasive growth hormone-secreting macroadenoma

Journal of Endocrinological Investigation

Volumn 30, Issue 7, 2007, Pages 541-545

  Luque Ramírez, Manu ^a   Paramo, C ^b   Varela da Costa, C ^c   Garcia Mayor R V ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Acromegaly; Invasive macroadenoma; Management; Pharmacoeconomics; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; BRAIN SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DRUG COST; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GALLSTONE FORMATION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INJECTION SITE PAIN; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; TREATMENT OUTCOME;

EID: 35348846609     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346346     Document Type: Article

References (22)

1. Etxabe J. Gaztambide J. Latorre P. Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest 1993, 16: 181-7.
2. Mestrón A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 2004, 151: 439-46.
3. Melmed S. Acromegaly. N Engl J Med 1990, 322: 966-77.
4. Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 2003, 10: 611-9.
5. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 86-91.
6. Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005, 153: 187-93.
7. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730-4.
8. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25: 102-52.
9. Weekes LM, Ho KK, Seale JP. Treatment options in acromegaly. Benefits and costs. Pharmacoeconomics 1996, 10: 453-9.
10. Abosch A, Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and longterm results. J Clin Endocrinol Metab 1998, 83: 3411-8.
11. Swearingen B, Barker II FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
12. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
13. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
14. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
15. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
16. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
17. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000, 85: 3779-85.
18. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005, 90: 4483-8.
19. Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract 2001, 7: 170-80.
20. Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004, 27: 1034-9.
21. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical treatment of acromegaly. Eur J Endocrinol 2005, 153: 737-40.
22. Ehrnborg C, Hakkaart-Van Roijen L, Jonsson B, Rutten FF, Bengtsson BA, Rosén T. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000, 17: 621-8.